Get the Stockscreener App
45.11
1.96%
-0.90
After Hours:
45.11
Ptc Therapeutics Inc stock is traded at $45.11, with a volume of 776.80K.
It is down -1.96% in the last 24 hours and up +10.70% over the past month.
See More
Previous Close:
$46.01
Open:
$47
24h Volume:
776.80K
Relative Volume:
1.10
Market Cap:
$3.30B
Revenue:
$900.45M
Net Income/Loss:
$-479.52M
P/E Ratio:
-5.215
EPS:
-8.65
Net Cash Flow:
$-230.14M
1W Performance:
+7.51%
1M Performance:
+10.70%
6M Performance:
+21.26%
1Y Performance:
+110.01%
1-Day Range:
$44.20
$47.23
1-Week Range:
$41.21
$47.24
52-Week Range:
$21.10
$47.24
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
45.11 | 3.30B | 900.45M | -479.52M | -230.14M | -8.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs - AOL
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Given New $52.00 Price Target at Robert W. Baird - MarketBeat
Baird raises PTC Therapeutics stock price target on drug prospects By Investing.com - Investing.com UK
PTC Therapeutics Sells Priority Review Voucher for $150M - TipRanks
PTC Therapeutics sells FDA priority review voucher for $150M - Investing.com
PTC Therapeutics sells FDA priority review voucher for $150M By Investing.com - Investing.com UK
PTC Therapeutics to Sell Priority Review Voucher for $150M After FDA Drug Approval | PTCT Stock News - StockTitan
Kronos, Idorsia plan layoffs; PTC shelves ALS drug - Yahoo Finance
PTC halts development of ALS drug after trial miss - The Pharma Letter
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
PTC's utreloxastat fails Phase 2 clinical study for ALS - MSN
PTC Therapeutics discontinues development of ALS drug after trial failure - Reuters
PTC Therapeutics to End Development of ALS Treatment - MarketWatch
PTC Therapeutics' ALS Drug Trial Fails Key Endpoints, Development Halted | PTCT Stock News - StockTitan
PTC Therapeutics (STU:BH3) Float Percentage Of Total Shares Outstanding : 64.01% (As of Nov. 26, 2024) - GuruFocus.com
Wells Fargo & Company Raises PTC Therapeutics (NASDAQ:PTCT) Price Target to $68.00 - MarketBeat
PTC Therapeutics Grants Stock Options, RSUs to New Employees at $41.96/Share | PTCT Stock News - StockTitan
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Grows Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Quest Partners LLC Raises Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
What is Kebilidi for AADC deficiency? - AADC News
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $62.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Cut to Hold at StockNews.com - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 7.4%Time to Sell? - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Additional Shares in PTC Therape - GuruFocus.com
PTC Therapeutics wins FDA nod for gene therapy - MSN
PTC Gets US FDA Approval For Brain-Delivered Gene Therapy - News & Insights
PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - MedCity News
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - AOL
PTC Therapeutics' Gene Therapy For AADC Deficiency Approved By FDA - Contract Pharma
AADC deficiency gene therapy, called Kebilidi, now approved in US - AADC News
FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency - Pharmacy Times
PTC wins US approval of gene therapy for fatal enzyme disorder - BioPharma Dive
PRV sweetens PTC approval of Kebilidi in AADC deficiency - BioWorld Online
FDA grants accelerated approval for PTC’s AADC deficiency gene therapy - Yahoo Finance
FDA nod for AADC deficiency gene therapy from PTC - The Pharma Letter
PTC Therapeutics wins FDA nod for gene therapy (PTCT:NASDAQ) - Seeking Alpha
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease - BioSpace
PTC gets FDA okay for first brain-delivered gene therapy - pharmaphorum
PTC Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder - Reuters.com
PTC Therapeutics Wins FDA Approval for Groundbreaking Brain Gene Therapy KEBILIDI | PTCT Stock News - StockTitan
PTC Therapeutics's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Barclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $40.38 Average Target Price from Analysts - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ptc Therapeutics Inc Stock (PTCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ZELDIS JEROME B | Director |
May 22 '24 |
Option Exercise |
26.42 |
20,000 |
528,400 |
34,500 |
| ZELDIS JEROME B | Director |
May 22 '24 |
Sale |
38.24 |
20,000 |
764,800 |
14,500 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
May 07 '24 |
Sale |
32.82 |
175 |
5,744 |
59,813 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Apr 19 '24 |
Sale |
24.89 |
3,361 |
83,669 |
225,807 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Apr 17 '24 |
Sale |
25.14 |
787 |
19,781 |
67,694 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Apr 17 '24 |
Sale |
25.14 |
1,307 |
32,851 |
229,168 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Apr 02 '24 |
Sale |
28.37 |
526 |
14,923 |
59,988 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
618 |
16,841 |
61,202 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
28 |
763 |
3,706 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 30 '24 |
Sale |
27.25 |
794 |
21,637 |
71,189 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):